Urinary proteomics and drug discovery in chronic kidney disease: A new perspective

Marco Prunotto, Gian Marco Ghiggeri, Giovanni Candiano, Pierre Lescuyer, Denis Hochstrasser, Solange Moll

Research output: Contribution to journalArticle

Abstract

Chronic kidney disease (CKD) is becoming a worldwide public health problem. The identification of a specific set of early biomarkers for CKD is extremely relevant to progress in disease knowledge, improving diagnosis, treatment, or development, and monitoring efficacy of new drugs. As kidney fibrosis can be considered the common pathological way to end stage renal failure, independent of the initial renal insult, these biomarkers are therefore biomarkers of early tubulo-interstitial fibrosis. The availability of a specific set of biomarkers for CKD is the mandatory condition to create new dedicated drugs and validate them in clinics without waiting years for a functional response in patients. We suggest here specific cohorts of patients where this early signature of fibrosis may be simpler to be identified.

Original languageEnglish
Pages (from-to)126-132
Number of pages7
JournalJournal of Proteome Research
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 7 2011

Fingerprint

Biomarkers
Drug Discovery
Chronic Renal Insufficiency
Proteomics
Fibrosis
Kidney
Public health
Medical problems
Pharmaceutical Preparations
Chronic Kidney Failure
Public Health
Availability
Monitoring
Therapeutics

Keywords

  • Biomarker
  • CKD
  • Drug discovery
  • Proteomics
  • Urine

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Urinary proteomics and drug discovery in chronic kidney disease : A new perspective. / Prunotto, Marco; Ghiggeri, Gian Marco; Candiano, Giovanni; Lescuyer, Pierre; Hochstrasser, Denis; Moll, Solange.

In: Journal of Proteome Research, Vol. 10, No. 1, 07.01.2011, p. 126-132.

Research output: Contribution to journalArticle

Prunotto, Marco ; Ghiggeri, Gian Marco ; Candiano, Giovanni ; Lescuyer, Pierre ; Hochstrasser, Denis ; Moll, Solange. / Urinary proteomics and drug discovery in chronic kidney disease : A new perspective. In: Journal of Proteome Research. 2011 ; Vol. 10, No. 1. pp. 126-132.
@article{488d3b08a7a2483dbf22c533bcef14f4,
title = "Urinary proteomics and drug discovery in chronic kidney disease: A new perspective",
abstract = "Chronic kidney disease (CKD) is becoming a worldwide public health problem. The identification of a specific set of early biomarkers for CKD is extremely relevant to progress in disease knowledge, improving diagnosis, treatment, or development, and monitoring efficacy of new drugs. As kidney fibrosis can be considered the common pathological way to end stage renal failure, independent of the initial renal insult, these biomarkers are therefore biomarkers of early tubulo-interstitial fibrosis. The availability of a specific set of biomarkers for CKD is the mandatory condition to create new dedicated drugs and validate them in clinics without waiting years for a functional response in patients. We suggest here specific cohorts of patients where this early signature of fibrosis may be simpler to be identified.",
keywords = "Biomarker, CKD, Drug discovery, Proteomics, Urine",
author = "Marco Prunotto and Ghiggeri, {Gian Marco} and Giovanni Candiano and Pierre Lescuyer and Denis Hochstrasser and Solange Moll",
year = "2011",
month = "1",
day = "7",
doi = "10.1021/pr100464q",
language = "English",
volume = "10",
pages = "126--132",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Urinary proteomics and drug discovery in chronic kidney disease

T2 - A new perspective

AU - Prunotto, Marco

AU - Ghiggeri, Gian Marco

AU - Candiano, Giovanni

AU - Lescuyer, Pierre

AU - Hochstrasser, Denis

AU - Moll, Solange

PY - 2011/1/7

Y1 - 2011/1/7

N2 - Chronic kidney disease (CKD) is becoming a worldwide public health problem. The identification of a specific set of early biomarkers for CKD is extremely relevant to progress in disease knowledge, improving diagnosis, treatment, or development, and monitoring efficacy of new drugs. As kidney fibrosis can be considered the common pathological way to end stage renal failure, independent of the initial renal insult, these biomarkers are therefore biomarkers of early tubulo-interstitial fibrosis. The availability of a specific set of biomarkers for CKD is the mandatory condition to create new dedicated drugs and validate them in clinics without waiting years for a functional response in patients. We suggest here specific cohorts of patients where this early signature of fibrosis may be simpler to be identified.

AB - Chronic kidney disease (CKD) is becoming a worldwide public health problem. The identification of a specific set of early biomarkers for CKD is extremely relevant to progress in disease knowledge, improving diagnosis, treatment, or development, and monitoring efficacy of new drugs. As kidney fibrosis can be considered the common pathological way to end stage renal failure, independent of the initial renal insult, these biomarkers are therefore biomarkers of early tubulo-interstitial fibrosis. The availability of a specific set of biomarkers for CKD is the mandatory condition to create new dedicated drugs and validate them in clinics without waiting years for a functional response in patients. We suggest here specific cohorts of patients where this early signature of fibrosis may be simpler to be identified.

KW - Biomarker

KW - CKD

KW - Drug discovery

KW - Proteomics

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=79951536568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951536568&partnerID=8YFLogxK

U2 - 10.1021/pr100464q

DO - 10.1021/pr100464q

M3 - Article

C2 - 20718506

AN - SCOPUS:79951536568

VL - 10

SP - 126

EP - 132

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 1

ER -